glp 1 derived from GLP-1 Agonists - What is it? Evolution of GLP‐1 Receptor Agonists

Easy to download and print

As the graphic illustrates, the index for new prescriptions in 2023 was 104, thus four points above the 100 mark

Multiple randomized controlled trials and meta-analyses in patients with type 2 diabetes and obesity demonstrate that GLP-1RA therapy either preserves or modestly increases bone mineral density (BMD) at key skeletal sites lumbar spine and hip, GLP-1RAs also favorably modulate bone turnover markers, increasing bone formation markers (P1NP, osteocalcin, bone-specific alkaline phosphatase) and reducing bone resorption markers (-CTX), suggesting a net positive or neutral effect on bone remodeling

Not Seeking Abstinence Only

The Medicines and Healthcare products Regulatory Agency (MHRA) has warned healthcare professionals to be aware of the potential risk of pulmonary aspiration in patients using glucagon-like peptide-1 (GLP-1) or dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists (GLP-1 RAs), who undergo surgery or procedures with general anaesthesia or deep sedation